Regulation of CCL5 expression in smooth muscle cells following arterial injury

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Liu, Huan ^a,b   Ning, Huan ^c   Men, Hongchao ^a   Hou, Rong ^c   Fu, Mingui ^d   Zhang, Hailin ^a   Liu, Jianguo ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Heibei North University Medical College   (China)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON REGULATORY FACTOR 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; CXCL10 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; CAROTID ARTERY INJURY; CHRONIC INFLAMMATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; MALE; NONHUMAN; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; COMMON CAROTID ARTERY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

RATTUS;

ANIMALS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELLS, CULTURED; CHEMOKINE CCL5; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; INTERFERON REGULATORY FACTOR-1; LIPOPOLYSACCHARIDES; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSFECTION;

EID: 84856091925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030873     Document Type: Article

References (51)

1. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
2. Glass CK, Witztum JL, (2001) Atherosclerosis. the road ahead. Cell 104: 503-516.
3. Libby P, (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
4. Hou R, Sibinga NE, (2009) Atrophin proteins interact with the Fat1 cadherin and regulate migration and orientation in vascular smooth muscle cells. J Biol Chem 284: 6955-6965.
5. Tedgui A, Mallat Z, (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581.
6. Baggiolini M, (1998) Chemokines and leukocyte traffic. Nature 392: 565-568.
7. Luster AD, (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445.
8. Rollins BJ, (1997) Chemokines. Blood 90: 909-928.
9. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, et al. (1988) A human T cell-specific molecule is a member of a new gene family. J Immunol 141: 1018-1025.
10. Appay V, Rowland-Jones SL, (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22: 83-87.
11. Levy JA, (2009) The unexpected pleiotropic activities of RANTES. J Immunol 182: 3945-3946.
12. Raines EW, Ferri N, (2005) Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46: 1081-1092.
13. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, et al. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94: 253-261.
14. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, et al. (2008) A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28: 1090-1096.
15. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, et al. (2007) Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27: 373-379.
16. Ohmori Y, Schreiber RD, Hamilton TA, (1997) Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 272: 14899-14907.
17. Lee AH, Hong JH, Seo YS, (2000) Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Biochem J 350 Pt 1: 131-138.
18. Erickson L, Crews G, Pan F, Fisniku O, Jang MS, et al. (2004) Unique gene expression profiles of heart allograft rejection in the interferon regulatory factor-1-deficient mouse. Transpl Immunol 13: 169-175.
19. Liu J, Guan X, Ma X, (2005) Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon {gamma}-induced RANTES/CCl5 expression in macrophages. J Biol Chem 280: 24347-24355.
20. Liu J, Ma X, (2006) Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and PU.1. J Biol Chem 281: 19188-19195.
21. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, et al. (2007) Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116: 1812-1820.
22. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
23. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, et al. (1996) The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 15: 1914-1923.
24. Weber KS, von Hundelshausen P, Clark-Lewis I, Weber PC, Weber C, (1999) Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol 29: 700-712.
25. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, et al. (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177: 1809-1814.
26. Kovacic JC, Gupta R, Lee AC, Ma M, Fang F, et al. (2010) Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 120: 303-314.
27. Koh SJ, Kim JY, Hyun YJ, Park SH, Chae JS, et al. (2009) Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects. Int J Cardiol 132: 102-108.
28. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H, (2006) Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 26: 194-199.
29. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, et al. (2001) RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777.
30. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, et al. (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106: 1523-1529.
31. Schroder K, Hertzog PJ, Ravasi T, Hume DA, (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189.
32. Giese NA, Gabriele L, Doherty TM, Klinman DM, Tadesse-Heath L, Contursi C, Epstein SL, Morse HC 3rd, (1997) Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med 186: 1535-1546.
33. Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, et al. (2007) Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am J Physiol Heart Circ Physiol 292: H2935-2943.
34. Bjorkbacka H, (2006) Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 17: 527-533.
35. Hertzog PJ, O'Neill LA, Hamilton JA, (2003) The interferon in TLR signaling: more than just antiviral. Trends Immunol 24: 534-539.
36. Sikorski K, Chmielewski S, Przybyl L, Heemann U, Wesoly J, et al. (2011) STAT1-mediated signal integration between IFN{gamma} and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol.
37. Erridge C, (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
38. Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ, (1996) Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem 271: 24286-24293.
39. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N, (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623-655.
40. Liu J, Cao S, Herman LM, Ma X, (2003) Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med 198: 1265-1276.
41. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, et al. (1993) Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75: 83-97.
42. Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW, (1996) The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 184: 2043-2048.
43. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, et al. (1997) Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6: 673-679.
44. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, et al. (1998) Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391: 700-703.
45. Ohteki T, Yoshida H, Matsuyama T, Duncan GS, Mak TW, et al. (1998) The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med 187: 967-972.
46. Lohoff M, Duncan GS, Ferrick D, Mittrucker HW, Bischof S, et al. (2000) Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J Exp Med 192: 325-336.
47. Clowes AW, Reidy MA, Clowes MM, (1983) Mechanisms of stenosis after arterial injury. Lab Invest 49: 208-215.
48. Hou R, Liu L, Anees S, Hiroyasu S, Sibinga NE, (2006) The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol 173: 417-429.
49. Gunther S, Alexander RW, Atkinson WJ, Gimbrone MA Jr, (1982) Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol 92: 289-298.
50. Zhang J, Qian X, Ning H, Yang J, Xiong H, et al. (2010) Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J Biol Chem 285: 21269-21281.
51. Schreiber E, Matthias P, Muller MM, Schaffner W, (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419.